Related Experiment Video
Updated: May 6, 2026

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
Published on: February 14, 2017
Mechanical loading reveals an intrinsic cardiomyocyte stiffness contribution to diastolic dysfunction in murine
Insights
Cardiometabolic diseases increase heart stiffness in cardiomyocytes, leading to diastolic dysfunction. This study reveals that increased cardiomyocyte stiffness is a key factor in heart failure, offering new therapeutic targets.
Area of Science:
- Cardiology
- Cell Biology
- Physiology
Background:
- Cardiometabolic diseases like diabetes and obesity are linked to heart failure with diastolic dysfunction.
- Current treatments for diastolic dysfunction offer limited efficacy.
- Understanding cardiomyocyte dysfunction is crucial for developing new therapies.
Purpose of the Study:
- To investigate the in vitro stiffness of cardiomyocytes from rodent hearts with diet-induced cardiometabolic disease and diastolic dysfunction.
- To correlate in vitro cardiomyocyte stiffness with in vivo diastolic dysfunction.
Main Methods:
- Male mice were fed a high-fat/high-sugar diet (HFSD) or control diet.
- Diastolic dysfunction was assessed using echocardiography (E/e' ratio).
- Isolated cardiomyocytes were functionally tested under non-loaded, loaded, and stretched conditions.
Main Results:
- HFSD mice showed diastolic dysfunction (35% higher E/e') and 70% stiffer cardiomyocytes compared to controls.
- A direct relationship was found between in vitro cardiomyocyte stiffness and in vivo dysfunction.
- Cardiomyocyte stiffness increased with load, stretch, and pacing, indicating altered myofilament-calcium interactions.
Conclusions:
- Intrinsic cardiomyocyte stiffness is a significant contributor to cardiac diastolic dysfunction in cardiometabolic disease.
- Mechanical dysfunction in cardiomyocytes is not detectable through non-loaded shortening analysis alone.
- Altered myofilament-calcium interactions likely underlie the increased cardiomyocyte stiffness observed in cardiometabolic disease.
Abstract:
Cardiometabolic syndromes including diabetes and obesity are associated with occurrence of heart failure with diastolic dysfunction. There are no specific treatments for diastolic dysfunction, and therapies to manage symptoms have limited efficacy. Understanding of the cardiomyocyte origins of diastolic dysfunction is an important priority to identify new therapeutics. The investigative goal was to experimentally define in vitro stiffness properties of isolated cardiomyocytes derived from rodent hearts exhibiting diastolic dysfunction in vivo in response to dietary induction of cardiometabolic disease. Male mice fed a high fat/sugar diet (HFSD vs control) exhibited diastolic dysfunction (echo E/e' doppler ratio). Intact paced cardiomyocytes were functionally investigated in three conditions: non-loaded, loaded and stretched. Mean stiffness of HFSD cardiomyocytes was 70% higher than control. E/e' for the origin hearts was elevated by 35%. A significant relationship was identified between in vitro cardiomyocyte stiffness and in vivo dysfunction severity. With conversion from non-loaded to loaded condition, the decrement in maximal sarcomere lengthening rate was more accentuated in HFSD cardiomyocytes (vs control). With stretch, the Ca2+ transient decay time course was prolonged. With increased pacing, cardiomyocyte stiffness was elevated, yet diastolic Ca2+ elevation was attenuated. Our findings show unequivocally that cardiomyocyte mechanical dysfunction cannot be detected by analysis of non-loaded shortening. Collectively, these findings demonstrate that a component of cardiac diastolic dysfunction in cardiometabolic disease is derived from cardiomyocyte stiffness. Differential responses to load, stretch and pacing suggest that a previously undescribed alteration in myofilament-Ca2+ interaction contributes to intrinsic cardiomyocyte stiffness in cardiometabolic disease.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

